The strategic use of novel smallpox vaccines in the post-eradication world

Expert Review of Vaccines

Volumn 10, Issue 7, 2011, Pages 1021-1035

  Golden, Joseph W ^a   Hooper, Jay W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

biological warfare; disease eradication; DNA vaccines; humoral immunity; orthopoxvirus; subunit vaccines; vaccination; variola virus; viral vectors; zoonoses

Indexed keywords

DNA VACCINE; SMALLPOX VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN A10L; VIRUS PROTEIN A27L; VIRUS PROTEIN A28L; VIRUS PROTEIN A33R; VIRUS PROTEIN B18R; VIRUS PROTEIN B5R; VIRUS PROTEIN C7L; VIRUS PROTEIN D8L; VIRUS PROTEIN H2L; VIRUS PROTEIN H3L; VIRUS PROTEIN L1R;

BIOLOGICAL WARFARE; CONTACT DERMATITIS; COWPOX VIRUS; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ECZEMA; HUMAN; INFECTION PREVENTION; MASS IMMUNIZATION; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMALLPOX; SMALLPOX VIRUS; VACCINATION; VACCINE PRODUCTION; VACCINIA; VACCINIA VIRUS; VIRUS IMMUNITY; ZOONOSIS;

DISEASE ERADICATION; HUMANS; SMALLPOX; SMALLPOX VACCINE; VACCINATION; VARIOLA VIRUS;

EID: 80051515823     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.46     Document Type: Review

References (163)

1. Moss B. Poxviruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott, Williams and Wilkins, Philadelphia, PA, USA, 2905-2946 (2007).
2. Damon I. Poxviruses In: Fields Virology. Knipe DM, Howley PM (Eds). Lippencott, Williams and Wilkins, Philadelphia, PA, USA, 2947-2976 (2007).
3. Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi ID. Smallpox and Its Eradication. World Health Organization, Geneva, Switzerland (1988).
4. Hopkins DR. The Greatest Killer: Smallpox in History, With a New Introduction. University of Chicago Press, Chicago, IL, USA (2002).
5. Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann. Intern. Med. 127(8 Pt 1), 635-642 (1997). (Pubitemid 127747201)
6. Eyler JM. Smallpox in history: the birth, death, and impact of a dread disease. J. Lab. Clin. Med. 142(4), 216-220 (2003). (Pubitemid 37449521)
7. Klebs AC, Lausanne MD. The historic evolution of variolation. The Johns Hopkins Hospital Bulletin 24(265), 1-66 (1913).
8. Dinc G, Ulman YI. The introduction of variolation A La Turca' to the West by Lady Mary Montagu and Turkeys contribution to this. Vaccine 25(21), 4261-4265 (2007). (Pubitemid 46635940)
9. Jenner E. Inquiry into the Causes and Effects of the Variolae Vaccine. Murray and Highley, London, UK (1798).
10. Dudgeon JA. Development of smallpox vaccine in England in the eighteenth and nineteenth Centuries. BMJ 1(5342), 1367-1372 (1963).
11. Nalca A, Hatkin JM, Garza NL et al. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res. 79(2), 121-127 (2008).
12. Appleyard G, Hapel AJ, Boulter EA. An antigenic difference between intracellular and extracellular rabbitpox virus. J. Gen. Virol. 13(1), 9-17 (1971).
13. Boulter EA. Protection against poxviruses. Proc. R. Soc. Med. 62(3), 295-297 (1969).
14. Turner GS, Squires EJ. Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus. J. Gen Virol. 13(1), 19-25 (1971).
15. Turner GS, Squires EJ, Murray HG. Inactivated smallpox vaccine. A comparison of inactivation methods. J. Hyg (Lond.) 68(2), 197-210 (1970).
16. Rivers TM, Ward SM. Jennerian prophylaxis by means of intradermal injections of culture vaccine virus. J. Exp. Med. 62(4), 549-560 (1935).
17. Rivers TM, Ward SM, Baird RD. Amount and duration of immunity induced by intradermal inoculation of cultured vaccine virus. J. Exp. Med. 69(6), 857-866 (1939).
18. Kempe CH, Fulginiti V, Minamitani M, Shinefeld H. Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78). Pediatrics 42(6), 980-985 (1968).
19. Wesley RB, Speers WC, Neff JM, Ruben FL, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. I. Clinical and serologic response to primary vaccination. Pediatric Res. 9(8), 624-628 (1975).
20. Speers WC, Wesley RB, Neff JM, Goldstein J, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. II. Clinical and serologic observations of response to revaccination with calf lymph vaccine. Pediatric Res. 9(8), 628-632 (1975).
21. Hochstein-Mintzel V, Hanichen T, Huber HC, Stickl H. An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola. Zentralbl. Bakteriol. Orig. A 230(3), 283-297 (1975).
22. McCurdy LH, Larkin BD, Martin JE, Graham BS. Modifed vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis. 38(12), 1749-1753 (2004). (Pubitemid 38781668)
23. Slifka MK. The future of smallpox vaccination: is MVA the key? Med. Immunol. (Lond.) 4(1), 2 (2005).
24. Hashizume S, Yoshizawa H, Morita M, Suzuki Kp-IGVQe, Vaccinia viruses as vectors for vaccine antigens. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In: Vaccinia Viruses as Vectors for Vaccine Antigens. Quainnan GV (Ed.). Elsevier Science Publishing Co, Amsterdam, The Netherlands, 421-428 (1985).
25. Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 24(47-48), 7009-7022 (2006). (Pubitemid 46107176)
26. Center for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, McIntyre L (Eds). Public Health Foundation, Washington, DC, USA (2006).
27. Shooter RA. Report on the Investigation into the Cause of the 1978 Birmingham Smallpox Occurrence. Her Majesty's Stationery Offce, London, UK (1980).
28. World Health Organization. No smallpox. Wkly Epidemiol. Rec. 54, 329-336 (1979).
29. Kortepeter MG, Parker GW. Potential biological weapons threats. Emerg. Infect. Dis. 5(4), 523-527 (1999). (Pubitemid 29418180)
30. Fenn EA. Biological warfare in eighteenth-Century North America: beyond Jeffery Amherst. J. Am. Hist. 86(4), 1552-1580 (2000).
31. Alibek K. Smallpox: a disease and a weapon. Int. J. Infect. Dis. 8(Suppl. 2), S3-S8 (2004). (Pubitemid 39445962)
32. Frischknecht F. The history of biological warfare. Human experimentation, modern nightmares and lone madmen in the twentieth Century. EMBO Rep. 4(Spec No.), S47-S52 (2003). (Pubitemid 36889424)
33. Shoham D, Wolfson Z. The Russian biological weapons program: vanished or disappeared? Crit Rev. Microbiol. 30(4), 241-261 (2004). (Pubitemid 39557582)
34. Graham B, Talent J. Bioterrorism: redefning prevention. Biosecur. Bioterror. 7(2), 125-126 (2009).
35. Domi A, Moss B. Cloning the vaccinia virus genome as a bacterial artifcial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc. Natl Acad. Sci. USA 99(19), 12415-12420 (2002).
36. Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science (New York) 297(5583), 1016-1018 (2002). (Pubitemid 34856035)
37. Wimmer E, Mueller S, Tumpey TM, Taubenberger JK. Synthetic viruses: a new opportunity to understand and prevent viral disease. Nat. Biotechnol. 27(12), 1163-1172 (2009).
38. Smith GL, McFadden G. Smallpox: anything to declare? Nat. Rev. Immunol. 2(7), 521-527 (2002) (Pubitemid 37328743)
39. Center for Diseaes Control and Prevention. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 50(RR-10), 1-25 (2001)
40. Center for Diseaes Control and Prevention. Recommendations for using smallpox vaccine in a prevent vaccinatino program: supplemental recommendation sof the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Morb. Mortal. Wkly Rep. 52(RR-7), 1-16 (2003).
41. Kwon N, Raven MC, Chiang WK et al Emergency physicians' perspectives on smallpox vaccination. Acad. Emerg. Med. 10(6), 599-605 (2003). (Pubitemid 36667062)
42. Schraeder TL, Campion EW. Smallpox vaccination-the call to arms. N. Engl J. Med. 348(5), 381-382 (2003).
43. Yih WK, Lieu TA, Rego VH et al. Attitudes of healthcare workers in U.S. hospitals regarding smallpox vaccination. BMC Public Health 3, 20 (2003).
44. Strikas RA, Neff LJ, Rotz L et al. US civilian smallpox preparedness and response program, 2003. Clin. Infect. Dis. 46(Suppl. 3), S157-S167 (2008). (Pubitemid 351590127)
45. Casey CG, Iskander JK, Roper MH et al Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 294(21), 2734-2743 (2005). (Pubitemid 41770103)
46. Clark PT, Levin S. The Smallpox vaccine injury compensation program. Clin. Infect. Dis. 46(Suppl. 3), S179-S181 (2008). (Pubitemid 351590129)
47. Kaplan EH, Craft DL, Wein LM. Emergency response to a smallpox attack: the case for mass vaccination. Proc. Natl Acad. Sci. USA 99(16), 10935-10940 (2002).
48. Meltzer MI, Damon I, LeDuc JW, Millar JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg. Infect. Dis. 7(6), 959-969 (2001). (Pubitemid 33115774)
49. O'Toole T, Mair M, Inglesby T V. Shining light on "Dark Winter". Clin. Infect. Dis. 34(7), 972-983 (2002).
50. Bicknell WJ. The case for voluntary smallpox vaccination. N. Engl. J. Med. 346(17), 1323-1325 (2002). (Pubitemid 34436087)
51. Handley L, Buller RM, Frey SE, Bellone C, Parker S. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev. Vaccines 8(7), 841-850 (2009).
52. Mortimer PP. Can postexposure vaccination against smallpox succeed? Clin. Infect. Dis. 36(5), 622-629 (2003). (Pubitemid 36259569)
53. Bicknell WJ, James K. Smallpox vaccination after a bioterrorism-based exposure. Clin. Infect. Dis. 37(3), 467 (2003).
54. Bicknell W, James K. The new cell culture smallpox vaccine should be offered to the general population. Rev. Med. Virol. 13(1), 5-15 (2003). (Pubitemid 36125501)
55. Fauci AS. Smallpox vaccination policy-the need for dialogue. N. Engl. J. Med. 346(17), 1319-1320 (2002). (Pubitemid 34429465)
56. Hilleman MR. Overview: cause and prevention in biowarfare and bioterrorism. Vaccine 20(25-26), 3055-3067 (2002).
57. Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des. Dev. Ther. 4, 71-79 (2010).
58. Weltzin R, Liu J, Pugachev KV et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat. Med. 9(9), 1125-1130 (2003). (Pubitemid 37173695)
59. ®, package insert. Acambis, Cambridge, UK.
60. Lane JM, Goldstein J. Adverse events occurring after smallpox vaccination. Semin. Pediatr. Infect. Dis. 14(3), 189-195 (2003). (Pubitemid 36994970)
61. Copeman PW, Wallace HJ. Eczema vaccinatum. BMJ 2(5414), 906-908 (1964).
62. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N. Engl. J. Med. 281(22), 1201-1208 (1969).
63. Centers for Disease Control and Prevention. Household transmission of vaccinia virus from contact with a military smallpox vaccinee-Illinois and Indiana, 2007. MMWR Morb. Mortal. Wkly Rep. 56(19), 478-481 (2007).
64. Monath TP, Frey SE. Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine 27(10), 1645-1650 (2009).
65. Kennedy JS, Greenberg RN. IMVAMUNE: modifed vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev. Vaccines 8(1), 13-24 (2009).
66. Earl PL, Americo JL, Wyatt LS et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428(6979), 182-185 (2004). (Pubitemid 38374314)
67. Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM. Short-and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 26(14), 1794-1804 (2008).
68. Earl PL, Americo JL, Wyatt LS et al. Recombinant modifed vaccinia virus Ankara provides durable protection against disease caused by an immunodefciency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 366(1), 84-97 (2007). (Pubitemid 47315810)
69. Antoine G, Scheifinger F, Dorner F, Falkner FG. The complete genomic sequence of the modifed vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244(2), 365-396 (1998). (Pubitemid 28384101)
70. Meisinger-Henschel C, Schmidt M, Lukassen S et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modifed vaccinia virus Ankara. J. Gen. Virol. 88(Pt 12), 3249-3259 (2007). (Pubitemid 350201834)
71. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their infuence on virulence. J. Gen Virol. 72 (Pt 5), 1031-1038 (1991).
72. Meisinger-Henschel C, Spath M, Lukassen S et al. Introduction of the six major genomic deletions of modifed vaccinia virus Ankara (MVA) into the parental vaccinia virus is not suffcient to reproduce an MVA-like phenotype in cell culture and in mice. J. Virol. 84(19), 9907-9919 (2010).
73. Zwilling J, Sliva K, Schwantes A, Schnierle B, Sutter G. Functional F11L and K1L genes in modifed vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells. Virology 404(2), 231-239 (2010)
74. US FDA Fast Track status for IMVAMUNE. Hum. Vaccin. 6(5), 368-372 (2010).
75. Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. The immunology of smallpox vaccines. Curr. Opin. Immunol. 21(3), 314-320 (2009).
76. Good RA, Zak SJ, Condie RM, Bridges RA. Clinical investigation of patients with agammaglobulinemia and hypogammaglobulinemia. Pediatr. Clin. North Am. 7, 397-433 (1960).
77. Fulginiti V, Kempe CH, Hathaway WE et al. Progressive vaccinia in immunologically defcient individuals. Birth Defects 4, 129-145 (1968).
78. Edghill-Smith Y, Golding H, Manischewitz J et al. Smallpox vaccine-induced antibodies are necessary and suffcient for protection against monkeypox virus. Nat. Med. 11(7), 740-747 (2005). (Pubitemid 41021206)
79. Panchanathan V, Chaudhri G, Karupiah G. Interferon function is not required for recovery from a secondary poxvirus infection. Proc. Natl Acad. Sci. USA 102(36), 12921-12926 (2005). (Pubitemid 41279465)
80. Panchanathan V, Chaudhri G, Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80(13), 6333-6338 (2006). (Pubitemid 43927436)
81. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79(21), 13454-13462 (2005). (Pubitemid 41508158)
82. McCausland MM, Benhnia MR, Crickard L et al. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antiviral Ther. 15(4), 661-675 (2010).
83. Davies DH, Liang X, Hernandez JE et al. Profling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl Acad. Sci. USA 102(3), 547-552 (2005). (Pubitemid 40282702)
84. Sette A, Grey H, Oseroff C et al. Defnition of epitopes and antigens recognized by vaccinia specifc immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 27(Suppl. 6), G21-G26 (2009).
85. Xu RH, Cohen M, Tang Y et al. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J. Exp. Med. 205(4), 981-992 (2008). (Pubitemid 351549892)
86. Golden JW, Hooper JW. Evaluating the orthopoxvirus type I interferon binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model. Clin. Vaccine Immunol. 17(11), 1656-1665 (2010).
87. + T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78(13), 7052-7060 (2004). (Pubitemid 38781543)
88. Isaacs SN. Improved smallpox vaccines. In: New Generation Vaccines. Levine MM, Dougan G, Good MF et al. (Eds). Informa Helthcare, New York, NY, USA, 838-850 (2010).
89. Berhanu A, Wilson RL, Kirkwood-Watts DL et al. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J. Virol. 82(7), 3517-3529 (2008). (Pubitemid 351429927)
90. Davies DH, McCausland MM, Valdez C et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 79(18), 11724-11733 (2005). (Pubitemid 41279291)
91. Braxton CL, Puckett SH, Mizel SB, Lyles DS. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J. Virol. 84(7), 3552-3561 (2010).
92. Buchman GW, Cohen ME, Xiao Y et al. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 28(40), 6627-6636 (2010).
93. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78(19), 10230-10237 (2004). (Pubitemid 39258347)
94. Fogg CN, Americo JL, Lustig S et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25(15), 2787-2799 (2007). (Pubitemid 46412575)
95. Heraud JM, Edghill-Smith Y, Ayala V et al. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177(4), 2552-2564 (2006). (Pubitemid 44201014)
96. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266(2), 329-339 (2000). (Pubitemid 30070637)
97. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306(1), 181-195 (2003). (Pubitemid 36293408)
98. Hooper JW, Ferro AM, Golden JW et al Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28(2), 494-511 (2009).
99. Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25(10), 1814-1823 (2007). (Pubitemid 46176327)
100. Kaufman DR, Goudsmit J, Holterman L et al. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J. Virol 82(14), 6829-6837 (2008). (Pubitemid 351977704)
101. Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential effcacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22(25-26), 3358-3366 (2004). (Pubitemid 39078753)
102. Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection effcacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355(2), 164-174 (2006). (Pubitemid 44692776)
103. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection effcacy of subunit-based smallpox vaccines using variola major antigens. Virology 371(1), 98-107 (2007).
104. Xiao Y, Aldaz-Carroll L, Ortiz AM et al A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25(7), 1214-1224 (2007). (Pubitemid 46027342)
105. Demkowicz WE, Maa JS, Esteban M. Identifcation and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J. Virol. 66(1), 386-398 (1992).
106. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254(1), 71-80 (1999). (Pubitemid 29391715)
107. Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325(2), 425-431 (2004). (Pubitemid 38902805)
108. Golden JW, Hooper JW. Heterogeneity in the A33 protein impacts the cross-protective effcacy of a candidate smallpox DNA vaccine. Virology 377(1), 19-29 (2008).
109. Aldaz-Carroll L, Xiao Y, Whitbeck JC et al. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J. Virol. 81(15), 8131-8139 (2007). (Pubitemid 47101499)
110. Biswas S, Kalanidhi AP, Ashok MS, Reddy GS, Srinivasan VA, Rangarajan PN. Evaluation of rabies virus neutralizing antibody titres induced by intramuscular inoculation of rabies DNA vaccine in mice and Bonnet monkeys (Macaca radiata). Indian J. Exp. Biol. 39(6), 533-536 (2001). (Pubitemid 32516095)
111. Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 27(5), 748-756 (2009).
112. Carnes AE, Williams JA. Plasmid DNA manufacturing technology. Recent Pat. Biotechnol. 1(2), 151-166 (2007).
113. Forde GM. Rapid-response vaccines-does DNA offer a solution? Nat. Biotechnol. 23(9), 1059-1062 (2005). (Pubitemid 41486383)
114. Boni J, Stalder J, Reigel F, Schupbach J. Detection of reverse transcriptase activity in live attenuated virus vaccines. Clin. Diagn. Virol. 5(1), 43-53 (1996). (Pubitemid 26109950)
115. Tsang SX, Switzer WM, Shanmugam V et al. Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps vaccines derived from chicken cells: investigation of transmission to vaccine recipients. J. Virol. 73(7), 5843-5851 (1999). (Pubitemid 29274871)
116. Grosenbach DW, Jordan R, King DS et al. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 26(7), 933-946 (2008).
117. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21(3), 346-351 (2009).
118. Wang S, Pal R, Mascola JR et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodefciency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350(1), 34-47 (2006). (Pubitemid 44183670)
119. Hensley LE, Mulangu S, Asiedu C et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 6(5), e1000904 (2010).
120. Wei CJ, Boyington JC, McTamney PM et al. Induction of broadly neutralizing H1N1 infuenza antibodies by vaccination. Science 329(5995), 1060-1064 (2010).
121. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 28(17), 2999-3007 (2010).
122. Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, Lu S. Heterologous HA DNA vaccine prime-inactivated infuenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype infuenza viruses. Vaccine 26(29-30), 3626-3633 (2008).
123. Richmond JF, Lu S, Santoro JC et al. Studies of the neutralizing activity and avidity of anti-human immunodefciency virus type 1 Env antibody elicited by DNA priming and protein boosting. J. Virol. 72(11), p9092-p9100 (1998).
124. Wang S, Arthos J, Lawrence JM et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodefciency virus type 1. J. Virol. 79(12), 7933-7937 (2005). (Pubitemid 40756832)
125. Essbauer S, Pfeffer M, Meyer H. Zoonotic poxviruses. Vet. Microbiol. 140(3-4), 229-236 (2010).
126. Rimoin AW, Mulembakani PM, Johnston SC et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl Acad. Sci. USA 107(37), 16262-16267 (2010).
127. Cho CT, Wenner HA. Monkeypox virus. Bacteriol. Rev. 37(1), 1-18 (1973).
128. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 4(1), 15-25 (2004). (Pubitemid 38057054)
129. Reed KD, Melski JW, Graham MB et al. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350(4), 342-350 (2004). (Pubitemid 38101629)
130. Egberink HF, Willemse A, Horzinek MC. Isolation and identifcation of a poxvirus from a domestic cat and a human contact case. Zentralbl. Veterinarmed B 33(3), 237-240 (1986).
131. Willemse A, Egberink HF. Transmission of cowpox virus infection from domestic cat to man. Lancet 1(8444), 1515 (1985). (Pubitemid 15068633)
132. Kurth A, Wibbelt G, Gerber HP, Petschaelis A, Pauli G, Nitsche A. Rat-to-elephant-to-human transmission of cowpox virus. Emerg. Infect. Dis. 14(4), 670-671 (2008). (Pubitemid 351520876)
133. Kurth A, Straube M, Kuczka A, Dunsche AJ, Meyer H, Nitsche A. Cowpox virus outbreak in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) with a time-delayed infection to humans. PLoS ONE 4(9), e6883 (2009).
134. Marennikova SS, Maltseva NN, Korneeva VI, Garanina VM. Pox infection in Carnivora of the family Felidae. Acta Virol. 19(3), 260 (1975).
135. Marennikova SS, Shelukhina EM, Fimina VA. Pox infection in white rats. Lab. Anim. 12(1), 33-36 (1978). (Pubitemid 9138457)
136. Glatz M, Richter S, Ginter-Hanselmayer G, Aberer W, Mullegger RR. Human cowpox in a veterinary student. Lancet Infect. Dis. 10(4), 288 (2010).
137. Bhanuprakash V, Venkatesan G, Balamurugan V et al. Zoonotic Infections of Buffalopox in India. Zoonoses and Public Health 57(7-8), e149-e155 (2009).
138. Trindade GS, Emerson GL, Carroll DS, Kroon EG, Damon IK. Brazilian vaccinia viruses and their origins. Emerg. Infect. Dis. 13(7), 965-972 (2007). (Pubitemid 47048066)
139. Singh RK, Hosamani M, Balamurugan V, Bhanuprakash V, Rasool TJ, Yadav MP. Buffalopox: an emerging and re-emerging zoonosis. Anim. Health Res. Rev. 8(1), 105-114 (2007).
140. Abrahao JS, Silva-Fernandes AT, Lima LS et al. Vaccinia virus infection in monkeys, Brazilian Amazon. Emerg. Infect. Dis. 16(6), 976-979 (2010).
141. Medaglia ML, Pessoa LC, Sales ER, Freitas TR, Damaso CR. Spread of cantagalo virus to northern Brazil. Emerg. Infect. Dis. 15(7), 1142-1143 (2009).
142. Silva-Fernandes AT, Travassos CE, Ferreira JM et al. Natural human infections with Vaccinia virus during bovine vaccinia outbreaks. J. Clin. Virol. 44(4), 308-313 (2009).
143. Croft DR, Sotir MJ, Williams CJ et al. Occupational risks during a monkeypox outbreak, Wisconsin, 2003. Emerg. Infect. Dis. 13(8), 1150-1157 (2007). (Pubitemid 47359157)
144. Kuntze A. Elephant pox and microsporum infection-two zoonoses of relevance to the zoo veterinarian. Presented at: European Association of Zoo-and Wildlife Veterinarians, Second scientifc meeting. Chester, UK, 21-24 May 1998.
145. Drexler I, Heller K, Wahren B, Erfe V, Sutter G. Highly attenuated modifed vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79 (Pt 2), 347-352 (1998). (Pubitemid 28048439)
146. Redding L, Weiner DB. DNA vaccines in veterinary use. Expert Rev. Vaccines 8(9), 1251-1276 (2009).
147. Gronvall GK, Trent D, Borio L, Brey R, Nagao L. The FDA animal effcacy rule and biodefense. Nat. Biotechnol. 25(10), 1084-1087 (2007). (Pubitemid 47538099)
148. Yang G, Pevear DC, Davies MH et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79(20), 13139-13149 (2005). (Pubitemid 41433232)
149. Atlas R, Rubin C, Maloy S, Daszak P, Colwell R, Hyde B. One health-attaining optimal health for people, animals and the environment. Microbe 5(9), 383-389 (2010).
150. Orent W. Will Monkeypox be the Next Smallpox? In: Los Angeles Times. Russ Stanton (Ed.). Los Angeles, CA, USA (2010).
151. Sassetti CM, Rubin EJ. The open book of infectious diseases. Nat. Med. 13(3), 279-280 (2007). (Pubitemid 46376667)
152. Garza NL, Hatkin JM, Livingston V et al. Evaluation of the effcacy of modifed vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine 27(40), 5496-5504 (2009).
153. Dupuy LC, Schmaljohn CS. DNA vaccines for biodefense. Expert Rev. Vaccines 8(12), 1739-1754 (2009).
154. Golden JW, Josleyn MD, Hooper JW. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 26(27-28), 3507-3515 (2008).
155. Rudraraju R, Ramsay AJ. Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection. Vaccine 28(31), 4997-5004 (2010).
156. Fang M, Cheng H, Dai Z, Bu Z, Sigal LJ. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 345(1), 231-243 (2006). (Pubitemid 43107587)
157. Shinoda K, Wyatt LS, Moss B. The neutralizing antibody response to the vaccinia virus A28 protein is specifcally enhanced by its association with the H2 protein. Virology 405(1), 41-49 (2010).
158. Graham BS, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194(12), 1650-1660 (2006). (Pubitemid 44901995)
159. Geier MR, Geier DA, Zahalsky AC. A review of hepatitis B vaccination. Expert Opin. Drug Safety 2(2), 113-122 (2003).
160. Abraham P, Mistry FP, Bapat MR et al. Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine 17(9-10), 1125-1129 (1999). (Pubitemid 29132945)
161. Martin JE, Sullivan NJ, Enama ME et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol. 13(11), 1267-1277 (2006). (Pubitemid 46768881)
162. Martin JE, Pierson TC, Hubka S et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a Phase 1 clinical trial. J. Infect. Dis. 196(12), 1732-1740 (2007). (Pubitemid 351411932)
163. Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an infuenza challenge in a double-blind randomised placebo-controlled Phase 1b clinical trial. Vaccine 27(18), 2506-2512 (2009).